TCEAL7 Antibody

What is TCEAL7 and what cellular functions does it regulate?

TCEAL7 (Transcription Elongation Factor A Like 7) is a nuclear protein belonging to the TFS-II protein family. It functions primarily as a transcriptional regulator with multiple documented roles including:

• In skeletal muscle, it acts as a muscle-specific gene that represses myoblast proliferation and promotes myogenic differentiation

• In normal cellular contexts, it plays a role in negative regulation of NF-kappa-B signaling at the basal level by modulating transcriptional activity of NF-kappa-B on target gene promoters

• It has been shown to interact with specific cell cycle regulators, particularly Cdk1, suggesting a role in cell cycle regulation

TCEAL7 has gained research interest due to its regulatory functions in muscle development and potential tumor suppressor activities in various cancers, making antibodies against this protein valuable research tools.

What are the structural characteristics of TCEAL7 that researchers should consider when selecting antibodies?

When selecting TCEAL7 antibodies, researchers should consider these key structural characteristics:

• Human TCEAL7 is a relatively small protein with 100 amino acid residues and a molecular mass of approximately 12.3 kDa

• Mouse Tceal7 shows 76% homology and 89% similarity to human TCEAL7 in protein sequence

• The protein contains four RxL motifs that were initially hypothesized to mediate cyclin interactions, though direct binding to cyclins has not been demonstrated

• Multiple functional domains exist within the protein, with the middle (aa34-76) and C-terminal (aa77-98) regions involved in Cdk1 binding

These structural features should guide antibody selection based on the specific epitopes and applications needed for your research goals.

In which tissues is TCEAL7 predominantly expressed and how does this affect immunodetection approaches?

TCEAL7 shows a tissue-specific expression pattern that researchers should consider when designing experiments:

• Highly expressed in normal and fetal brain tissues

• Weakly expressed in uterus and ovary

• Functions as a muscle-specific gene, with significant expression in skeletal muscle

This differential expression profile means that immunodetection protocols should be optimized differently depending on the tissue under investigation. For high-expression tissues like brain and muscle, dilution series testing is essential to prevent signal saturation. For low-expression tissues like uterus and ovary, more sensitive detection methods and higher antibody concentrations may be required, along with appropriate positive controls to validate results.

What are the most common applications for TCEAL7 antibodies in research?

TCEAL7 antibodies are employed in several key research applications:

• Western Blot (WB): The most widely used application for detecting TCEAL7 protein expression levels and post-translational modifications

• Enzyme-Linked Immunosorbent Assay (ELISA): Used for quantitative measurement of TCEAL7 in biological samples

• Immunohistochemistry (IHC): Applied for tissue localization studies to examine expression patterns across different cell types

• Co-immunoprecipitation (Co-IP): Used to study protein-protein interactions, particularly valuable for investigating TCEAL7's interaction with Cdk1 and potentially other binding partners

These applications can be optimized for specific research questions regarding TCEAL7's role in muscle development, cell cycle regulation, or disease contexts.

What species reactivity should researchers consider when selecting TCEAL7 antibodies?

When selecting TCEAL7 antibodies, consider that:

• TCEAL7 orthologs have been reported in multiple species including mouse, rat, bovine, and chimpanzee

• There is a 76% homology and 89% similarity between human and mouse TCEAL7 proteins

• Commercial antibodies vary in their cross-reactivity profiles, with some showing reactivity to human and mouse only, while others may react with rabbit, rat, bovine, dog, horse, pig, and yeast samples

Always verify the specific cross-reactivity of your antibody for your experimental model. When studying evolutionarily conserved functions of TCEAL7, selecting antibodies that recognize epitopes in conserved regions may allow for cross-species applications.

How can researchers validate the specificity of TCEAL7 antibodies for their experimental systems?

Thorough validation of TCEAL7 antibodies requires a multi-faceted approach:

• Knockout/knockdown controls:

  • Use TCEAL7 knockout or siRNA-knockdown samples as negative controls to verify antibody specificity

  • Observe the expected reduction or absence of signal in these samples

• Overexpression validation:

  • Utilize overexpression systems (e.g., transgenic models like the MCK 6.5 kb-HA-Tceal7 model) to confirm detection of increased TCEAL7 levels

  • Tag-based detection (e.g., HA-tag) can provide orthogonal validation

• Peptide competition assays:

  • Pre-incubate the antibody with excess TCEAL7 peptide corresponding to the antibody epitope

  • This should abolish specific binding if the antibody is truly TCEAL7-specific

• Multiple antibody comparison:

  • Use antibodies from different sources or targeting different epitopes of TCEAL7

  • Consistent results across different antibodies increase confidence in specificity

These validation steps are critical because TCEAL7 is relatively small and belongs to a family of related proteins, increasing the risk of cross-reactivity with other TCEAL family members.

What are the optimal experimental conditions for studying TCEAL7's interaction with Cdk1?

Based on published methodologies, the following approaches have proven effective for studying TCEAL7-Cdk1 interactions:

• Co-immunoprecipitation (Co-IP):

  • Overexpress tagged versions (e.g., 3xHA-Tceal7 and 6×Myc-Cdk1) for enhanced detection

  • Use stringent washing conditions with RIPA or modified RIPA buffer to minimize non-specific interactions

  • Include appropriate controls such as normal IgG precipitations

• GST-pulldown assays:

  • Express and purify GST-tagged TCEAL7 from E. coli using GST affinity beads

  • Incubate with cell lysates expressing Cdk1 or with purified Cdk1

  • This approach has successfully demonstrated the direct interaction between TCEAL7 and Cdk1

• Mapping interaction domains:

  • Create deletion mutants of both TCEAL7 and Cdk1 to identify specific interaction domains

  • For TCEAL7, the regions aa34-76 (M domain) and aa77-98 (C domain) have been identified as Cdk1-binding regions

  • For Cdk1, the M domain (aa86-208) mediates the interaction with TCEAL7

These methods can be adapted to investigate whether TCEAL7 competes with other Cdk1 binding partners or how this interaction affects Cdk1 kinase activity.

How can researchers design experiments to investigate TCEAL7's role in skeletal muscle development?

To investigate TCEAL7's role in skeletal muscle development, consider these experimental approaches:

These approaches can provide comprehensive insights into TCEAL7's regulatory mechanisms in muscle development.

What methodological considerations are important when using TCEAL7 antibodies for subcellular localization studies?

When conducting subcellular localization studies with TCEAL7 antibodies, researchers should consider:

• Fixation and permeabilization optimization:

  • TCEAL7 is primarily a nuclear protein, requiring adequate nuclear permeabilization

  • Compare paraformaldehyde fixation (typically 4%) with methanol fixation to determine optimal epitope accessibility

  • Test different permeabilization agents (Triton X-100, saponin, digitonin) at varying concentrations

• Subcellular fractionation controls:

  • Include established markers for different cellular compartments (nuclear, cytoplasmic, membrane)

  • For TCEAL7, nuclear markers like HDAC1 or lamin B1 serve as appropriate co-localization controls

• Antibody validation in fractionation experiments:

  • Perform Western blot on subcellular fractions to verify antibody specificity in each compartment

  • TCEAL7 should predominantly appear in the nuclear fraction but potentially in other compartments depending on cell type or condition

• Confocal microscopy considerations:

  • Use deconvolution or super-resolution techniques for precise nuclear localization

  • Consider co-staining with DNA dyes (DAPI, Hoechst) and other nuclear compartment markers

• Dynamic localization studies:

  • Monitor potential localization changes during cell cycle progression or differentiation

  • Time-course experiments may reveal regulated nuclear import/export of TCEAL7

These methodological considerations help ensure accurate interpretation of TCEAL7's subcellular distribution.

How can researchers effectively study TCEAL7's role in the negative regulation of NF-κB signaling?

To investigate TCEAL7's role in NF-κB signaling regulation, employ these methodological approaches:

• Reporter gene assays:

  • Utilize NF-κB responsive luciferase reporters in cells with manipulated TCEAL7 levels

  • Measure activity under basal conditions and following NF-κB pathway stimulation (e.g., TNF-α, IL-1β)

  • Compare results across multiple cell types relevant to TCEAL7 expression (brain, muscle, ovary)

• Chromatin immunoprecipitation (ChIP):

  • Use TCEAL7 antibodies for ChIP to identify genomic regions where TCEAL7 associates

  • Perform parallel ChIP for NF-κB p65 subunit

  • Sequential ChIP can determine if TCEAL7 and NF-κB co-occupy the same genomic regions

• Protein-protein interaction analysis:

  • Investigate whether TCEAL7 directly interacts with NF-κB components

  • Use immunoprecipitation with TCEAL7 antibodies followed by Western blot for p65, p50, IκB, etc.

  • Determine if interactions are direct or part of larger protein complexes

• Biochemical signaling studies:

  • Monitor IκB phosphorylation and degradation in response to stimuli

  • Examine p65 nuclear translocation using subcellular fractionation and TCEAL7 antibodies

  • Assess post-translational modifications of NF-κB components in relation to TCEAL7 levels

• Target gene expression analysis:

  • Measure expression of known NF-κB target genes using qRT-PCR or RNA-seq

  • Compare expression patterns in cells with normal, overexpressed, or knocked-down TCEAL7

These approaches provide mechanistic insight into how TCEAL7 modulates NF-κB signaling at the molecular level.

What are the common challenges with TCEAL7 detection in Western blots and how can they be addressed?

Researchers frequently encounter these challenges when using TCEAL7 antibodies in Western blots:

• Detection of the small protein size (12.3 kDa):

  • Use higher percentage gels (15-20%) or gradient gels

  • Optimize transfer conditions for small proteins (lower voltage, longer time)

  • Consider specialized membranes with smaller pore sizes for better retention

• Cross-reactivity with other TCEAL family members:

  • Select antibodies raised against unique regions of TCEAL7

  • Include positive controls from tissues with known high TCEAL7 expression (brain)

  • Run parallel blots with TCEAL7 knockout/knockdown samples

• Multiple bands or unexpected molecular weights:

  • Investigate potential post-translational modifications (phosphorylation sites have been reported)

  • Check for alternative splice variants in your experimental system

  • Optimize sample preparation to prevent degradation or aggregation

• Weak signal in tissues with low expression:

  • Increase protein loading for tissues like uterus or ovary where expression is weak

  • Use enhanced chemiluminescence detection systems or more sensitive fluorescent detection

  • Consider immunoprecipitation before Western blot to concentrate the target protein

• Optimization table for TCEAL7 Western blot conditions:

How can researchers optimize TCEAL7 immunoprecipitation protocols for studying protein-protein interactions?

To optimize immunoprecipitation of TCEAL7 and its interaction partners:

• Antibody selection and immobilization:

  • Test multiple TCEAL7 antibodies as different epitopes may be masked in protein complexes

  • Compare direct antibody conjugation to beads versus indirect capture with Protein A/G

  • For the TCEAL7-Cdk1 interaction, both approaches have been successful

• Lysis conditions optimization:

  • Start with gentler lysis buffers (NP-40 or CHAPS-based) to preserve weaker interactions

  • Compare with more stringent conditions (RIPA) to eliminate non-specific binding

  • The interaction between TCEAL7 and Cdk1 is sufficiently robust to withstand standard IP conditions

• Cross-linking considerations:

  • For transient interactions, consider using cross-linking agents before lysis

  • Formaldehyde or DSP (dithiobis(succinimidyl propionate)) can stabilize complexes

  • Test different cross-linker concentrations and reaction times

• Controls and validation:

  • Always include isotype control antibodies (normal IgG) to distinguish specific from non-specific binding

  • Use TCEAL7 knockout or knockdown samples as negative controls

  • For confirming the TCEAL7-Cdk1 interaction, overexpressed tagged versions (3xHA-Tceal7 and 6×Myc-Cdk1) provide clear validation

• Sequential immunoprecipitation:

  • For complex multi-protein interactions, use sequential IP (first with TCEAL7 antibody, then with antibody against suspected interaction partner)

  • This approach can help verify direct versus indirect interactions

These optimized approaches can help elucidate TCEAL7's role in protein complexes that regulate muscle development and other cellular processes.